Skip to main content
. Author manuscript; available in PMC: 2020 Sep 1.
Published in final edited form as: Pharmacol Ther. 2019 May 7;201:25–38. doi: 10.1016/j.pharmthera.2019.05.001

Figure 2: Effects of cannabinoid ligands on the central nervous system and peripheral nervous system.

Figure 2:

Activation of the cannabinoid 1 receptor (CB1) and cannabinoid 2 receptor (CB2) by cannabinoid ligands inhibits production of adenylate cyclase via activation of a coupled Gi/G0 G-protein subunit. CB1/2 activation also promotes exocytosis of a variety of neurotransmitters, which act broadly on the central and peripheral nervous system (CNS and PNS), perhaps by modulation of calcium and potassium transport.